AR086738A1 - USE OF AN ANTIBODY ANTI-CD20 OF GREAT CYTOTOXICITY FOR ANTIBODY DEPENDENT CELLULAR MEDIATION (ADCC) IN THE TREATMENT OF WALDENSTRÖM DISEASE - Google Patents

USE OF AN ANTIBODY ANTI-CD20 OF GREAT CYTOTOXICITY FOR ANTIBODY DEPENDENT CELLULAR MEDIATION (ADCC) IN THE TREATMENT OF WALDENSTRÖM DISEASE

Info

Publication number
AR086738A1
AR086738A1 ARP120102258A ARP120102258A AR086738A1 AR 086738 A1 AR086738 A1 AR 086738A1 AR P120102258 A ARP120102258 A AR P120102258A AR P120102258 A ARP120102258 A AR P120102258A AR 086738 A1 AR086738 A1 AR 086738A1
Authority
AR
Argentina
Prior art keywords
antibody
waldenström
adcc
disease
treatment
Prior art date
Application number
ARP120102258A
Other languages
Spanish (es)
Inventor
Le Garf-Tavernier Magali
De Romeuf Christophe
Merle-Beral Helene
Vieillard Vincent
Leblond Veronique
Original Assignee
Lfb Biotechnologies
Univ Paris 6 Pierre Et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies, Univ Paris 6 Pierre Et Marie Curie filed Critical Lfb Biotechnologies
Publication of AR086738A1 publication Critical patent/AR086738A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpo monoclonal dirigido contra el antígeno CD20. Dicho anticuerpo posee una gran citotoxicidad para la mediación celular dependiente de anticuerpos (ADCC) y/o tiene capacidad para activar las células efectoras con mayor expresión de FcgRlll, y que poseen una región Fc en la cual al menos un 60% de los oligosacáridos no están fucosilados, para su uso en el tratamiento de la enfermedad de Waldenström. Reivindicación 1: Anticuerpo monoclonal dirigido contra el antígeno CD20, caracterizado porque dicho anticuerpo tiene citotoxicidad mediada por células dependiente de anticuerpos (ADCC) y/o una capacidad para activar las células efectoras que expresan FcgRlll incrementada, y posee una región Fc en donde al menos 60% de los oligosacáridos son no fucosilados, para su utilización en el tratamiento de la enfermedad de Waldenström.Monoclonal antibody directed against the CD20 antigen. Said antibody has a high cytotoxicity for antibody-dependent cell mediation (ADCC) and / or has the capacity to activate effector cells with greater FcgRlll expression, and which possess an Fc region in which at least 60% of the oligosaccharides do not are fucosylated, for use in the treatment of Waldenström disease. Claim 1: Monoclonal antibody directed against the CD20 antigen, characterized in that said antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) and / or an ability to activate effector cells expressing increased FcgRlll, and possesses an Fc region where at least 60% of oligosaccharides are non-fucosylated, for use in the treatment of Waldenström disease.

ARP120102258A 2011-06-22 2012-06-22 USE OF AN ANTIBODY ANTI-CD20 OF GREAT CYTOTOXICITY FOR ANTIBODY DEPENDENT CELLULAR MEDIATION (ADCC) IN THE TREATMENT OF WALDENSTRÖM DISEASE AR086738A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101931A FR2976811A1 (en) 2011-06-22 2011-06-22 USE OF A HIGH ADCC ANTI-CD20 ANTIBODY FOR THE TREATMENT OF WALDENSTROM'S DISEASE

Publications (1)

Publication Number Publication Date
AR086738A1 true AR086738A1 (en) 2014-01-22

Family

ID=46508094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102258A AR086738A1 (en) 2011-06-22 2012-06-22 USE OF AN ANTIBODY ANTI-CD20 OF GREAT CYTOTOXICITY FOR ANTIBODY DEPENDENT CELLULAR MEDIATION (ADCC) IN THE TREATMENT OF WALDENSTRÖM DISEASE

Country Status (4)

Country Link
AR (1) AR086738A1 (en)
FR (1) FR2976811A1 (en)
TW (1) TW201309728A (en)
WO (1) WO2012175874A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3012453B1 (en) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement CHIMERIC PROTEIN FOR THE TREATMENT OF AMYLOSIS
CN111363043B (en) * 2020-04-09 2021-07-23 福州迈新生物技术开发有限公司 anti-CD 20 protein monoclonal antibody, cell line, preparation method and application thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2568899T3 (en) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
ES2252261T3 (en) 2000-06-28 2006-05-16 Glycofi, Inc. METHODS TO PRODUCE MODIFIED GLICOPROTEINS.
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US6994292B2 (en) 2002-10-18 2006-02-07 The Procter & Gamble Company Dispensing apparatus for web material
EP1587921B1 (en) 2003-01-22 2010-07-28 GlycArt Biotechnology AG Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US20050160485A1 (en) 2003-03-18 2005-07-21 Kyowa Hakko Kogyo Co., Ltd. Mouse in which genome is modified
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
EA202091901A1 (en) 2003-11-05 2020-11-24 Роше Гликарт Аг ANTIBODIES WITH INCREASED AFFINITY TO BINDING WITH THE Fc-RECEPTOR AND EFFECTORAL FUNCTION
US20060223147A1 (en) 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
FR2879204B1 (en) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
DK1945666T3 (en) 2005-10-21 2013-07-01 Genzyme Corp Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods for their preparation and use thereof
SI1945665T1 (en) 2005-10-21 2012-03-30 Genzyme Corp Antibody-based therapeutics with enhanced adcc activity
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
WO2007099988A1 (en) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-FUCOSYLTRANSFERASE MUTANT AND USE THEREOF
FR2915398B1 (en) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "SET OF MEANS FOR THE TREATMENT OF MALIGNANT PATHOLOGY, AUTOIMMUNE DISEASE OR INFECTIOUS DISEASE"
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
AU2009242453B2 (en) 2008-05-02 2014-12-04 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
TWI409079B (en) * 2009-08-14 2013-09-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with bendamustine
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points

Also Published As

Publication number Publication date
TW201309728A (en) 2013-03-01
FR2976811A1 (en) 2012-12-28
WO2012175874A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
AR068818A1 (en) COMBINATION THERAPY WITH ANTI-CD20, TYPE I AND TYPE II ANTIBODIES FOR THE TREATMENT OF CANCER, USE, KIT
CY1123229T1 (en) USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME
CL2017001580A1 (en) Antibody or antibody fragment against humanized antibody cd38, conjugated to the antibody with a cytotoxic compound pharmaceutical composition with said antibodies using antibodies to treat cancer or autoimmune disease method to diagnose cancer polynucleotide vector and host cell.
AR072947A1 (en) COMBINATION THERAPY OF AN ANTI-CD20 TYPE II ANTIBODY WITH CYTOTOXICITY, INCREASED ANTIBODY DEPENDENT CELL (CCDA), PHARMACEUTICAL COMPOSITION, ANTI-CD20 TYPE II ANTIBODY
ES2944597T3 (en) Enhanced Efficacy Immune Effector Cell Therapies
MX2022008288A (en) Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof.
CL2016000376A1 (en) Anti-prlr antibodies and their uses
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
PE20161217A1 (en) ANTI-CD3 ANTIBODIES AND METHODS OF USE
AR077866A1 (en) COMBINATION THERAPY OF A CD20 AFUCOSILATED AND BENDAMUSTINE ANTIBODY
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
PE20181399A1 (en) ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
CL2016002444A1 (en) Solar cell with a plurality of sub cells combined with a metallization structure.
CL2008003788A1 (en) Pharmaceutical composition comprising a) the humanized b-ly1 antibody (anti-cd20 / human b-lymphocyte / bp35 restricted referencing antigen, type ii), b) optionally from 0.001% to 1% w / v of at least one surfactant, and c) 1 to 100 mm of a buffer; use to treat cd20-related diseases.
CR10558A (en) ANTAGONIST ANTIBODY AGAINST EPHA2 FOR CANCER TREATMENT
AR074220A1 (en) ANTITUMORAL COMBINATIONS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE CD38 AND VINCRISTINE AND USE
PE20130826A1 (en) MOSQUITO TRAP
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
NI201300057A (en) FC MUTANTS OF ANTIBODIES RESISTANT TO ACTIVE PROTEASES
CR10347A (en) ANTIBODIES AGAINST PEPTIDOB-AMILOID
ECSP13013084A (en) USE OF ANTI-CD19 ANTIBODY IMMUNOCATED WITH MAITANSINOID FOR THE TREATMENT OF SYMPTOM TUMORS OF CELLS B
BR112013005145A2 (en) anti-cxcl13 antibodies and methods for their use
AR061986A1 (en) CELLULAR DEATH INDUCTIVE AGENTS
WO2008121876A3 (en) Non-fucosylated antibodies
CO2021007691A2 (en) Antagonist monoclonal antibodies against cd40 and their uses

Legal Events

Date Code Title Description
FB Suspension of granting procedure